[go: up one dir, main page]

CY1116811T1 - Λιποσωμα ιρινοτεκανης ή του υδροχλωριδιου αυτης και μεθοδος παρασκευης αυτου - Google Patents

Λιποσωμα ιρινοτεκανης ή του υδροχλωριδιου αυτης και μεθοδος παρασκευης αυτου

Info

Publication number
CY1116811T1
CY1116811T1 CY20151100943T CY151100943T CY1116811T1 CY 1116811 T1 CY1116811 T1 CY 1116811T1 CY 20151100943 T CY20151100943 T CY 20151100943T CY 151100943 T CY151100943 T CY 151100943T CY 1116811 T1 CY1116811 T1 CY 1116811T1
Authority
CY
Cyprus
Prior art keywords
hydrochloride
producing
liposome
irinotecan liposome
irinotecan
Prior art date
Application number
CY20151100943T
Other languages
English (en)
Inventor
Xinyong Tong
Guofeng Lei
Chengxia Yu
Liang Chen
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of CY1116811T1 publication Critical patent/CY1116811T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Αποκαλύπτονται ένα λιπόσωμα ιρινοτεκάνης ή του υδροχλωριδίου αυτής και μέθοδος παρασκευής αυτού. Το λιπόσωμα περιλαμβάνει ιρινοτεκάνη ή το υδροχλωρίδιο αυτής, ουδέτερο φωσφολιπίδιο και χοληστερόλη, όπου η αναλογία βάρους της χοληστερόλης προς το ουδέτερο φωσφολιπίδιο είναι 1:3-5. Το αναφερθέν λιπόσωμα παρασκευάζεται με μέθοδο κλίσης ιόντων.
CY20151100943T 2009-12-03 2015-10-21 Λιποσωμα ιρινοτεκανης ή του υδροχλωριδιου αυτης και μεθοδος παρασκευης αυτου CY1116811T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09851784.0A EP2508170B1 (en) 2009-12-03 2009-12-03 Liposome of irinotecan or its hydrochloride and preparation method thereof
PCT/CN2009/075298 WO2011066684A1 (zh) 2009-12-03 2009-12-03 伊立替康或盐酸伊立替康脂质体及其制备方法

Publications (1)

Publication Number Publication Date
CY1116811T1 true CY1116811T1 (el) 2017-03-15

Family

ID=44114598

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100943T CY1116811T1 (el) 2009-12-03 2015-10-21 Λιποσωμα ιρινοτεκανης ή του υδροχλωριδιου αυτης και μεθοδος παρασκευης αυτου

Country Status (21)

Country Link
US (2) US20120282325A1 (el)
EP (1) EP2508170B1 (el)
JP (1) JP5645954B2 (el)
KR (2) KR101780915B1 (el)
CN (1) CN102271659B (el)
AU (1) AU2009356132B2 (el)
BR (1) BR112012012151B8 (el)
CA (1) CA2782911C (el)
CY (1) CY1116811T1 (el)
DK (1) DK2508170T3 (el)
ES (1) ES2547698T3 (el)
HR (1) HRP20150911T1 (el)
HU (1) HUE027467T2 (el)
MX (1) MX2012005775A (el)
PL (1) PL2508170T3 (el)
PT (1) PT2508170E (el)
RU (1) RU2526114C2 (el)
SI (1) SI2508170T1 (el)
SM (1) SMT201500245B (el)
WO (1) WO2011066684A1 (el)
ZA (1) ZA201203316B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935066B (zh) * 2011-08-16 2014-09-17 齐鲁制药有限公司 一种伊立替康脂质体制剂及其制备方法
HRP20191683T1 (hr) 2011-10-21 2019-12-13 Jazz Pharmaceuticals Res Llc Liofilizirani liposomi
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
RU2014144945A (ru) * 2012-04-10 2016-05-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Бис-полимерные липид-пептидные конъюгаты и наночастицы из них
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CN102697720B (zh) * 2012-06-29 2014-01-15 海南灵康制药有限公司 盐酸伊立替康脂质纳米粒注射剂
CN103181898B (zh) * 2012-11-23 2016-03-09 杭州师范大学 一种奥沙利铂脂质体及其应用
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
HK1257216A1 (zh) 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
BR112018006922B1 (pt) * 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento
WO2017138023A1 (en) 2016-02-09 2017-08-17 Sun Pharmaceutical Industries Ltd. Perfusion system
CN107281102A (zh) * 2016-04-11 2017-10-24 江苏竞诺择生物医药科技有限公司 一种用于结直肠肿瘤治疗的药物微粒组合物
CN107456456A (zh) * 2016-06-03 2017-12-12 江苏恒瑞医药股份有限公司 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
CN118416082A (zh) * 2016-06-28 2024-08-02 应急生物防御行动兰辛有限责任公司 布林西多福韦的制剂
CN106109415B (zh) * 2016-07-26 2019-01-29 金华市人民医院 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用
CA3036235A1 (en) * 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions
RS63400B1 (sr) * 2016-10-28 2022-08-31 Servier Lab Lipozomska formulacija za upotrebu u lečenju kancera
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
US10722465B1 (en) * 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
JP7364561B2 (ja) 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
CN109675047B (zh) * 2019-01-07 2020-12-04 中国科学院化学研究所 一种对具有游离羟基的化合物进行脂质体修饰的方法
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
US11273124B2 (en) * 2019-05-23 2022-03-15 Brown University Antifungal nanoparticles for targeted treatment of fungal infections
CN114177278A (zh) * 2021-10-18 2022-03-15 山东多美康生物医药有限公司 脂质体制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
CA2346879A1 (en) * 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
EP1443900B1 (en) * 2001-11-13 2012-05-23 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
RU2424792C2 (ru) * 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
AP2255A (en) * 2004-06-01 2011-07-21 Yakult Honsha Kk Irinotecan preparation.
CN1326525C (zh) * 2004-11-26 2007-07-18 复旦大学 10－羟基喜树碱长循环脂质体及其冻干制剂
WO2007076117A2 (en) * 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
CA2658107A1 (en) * 2006-07-17 2008-01-24 Syntha Corporation Systems and methods for calculating and predicting near term production cost, incremental heat rate, capacity and emissions of electric generation power plants based on current operating and, optionally, atmospheric conditions
CN101019834A (zh) * 2006-12-31 2007-08-22 西安力邦医药科技有限责任公司 注射用7－乙基－10羟基喜树碱脂质体的制备方法
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
WO2008114274A1 (en) 2007-03-19 2008-09-25 Fresenius Kabi Onclology Ltd. Proliposomal and liposomal compositions
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物

Also Published As

Publication number Publication date
CA2782911C (en) 2016-08-23
HK1159482A1 (en) 2012-08-03
KR101780915B1 (ko) 2017-09-21
CA2782911A1 (en) 2011-06-09
SMT201500245B (it) 2015-10-30
AU2009356132A1 (en) 2012-06-21
BR112012012151A2 (pt) 2016-04-12
RU2012123875A (ru) 2014-01-20
EP2508170B1 (en) 2015-07-29
SI2508170T1 (sl) 2015-12-31
DK2508170T3 (en) 2015-09-21
HRP20150911T1 (hr) 2015-10-23
JP5645954B2 (ja) 2014-12-24
HUE027467T2 (en) 2016-10-28
MX2012005775A (es) 2012-06-13
US20120282325A1 (en) 2012-11-08
PT2508170E (pt) 2015-10-16
BR112012012151B8 (pt) 2021-05-25
US10022365B2 (en) 2018-07-17
ES2547698T3 (es) 2015-10-08
EP2508170A1 (en) 2012-10-10
EP2508170A4 (en) 2014-01-15
US20170189392A1 (en) 2017-07-06
CN102271659B (zh) 2013-09-18
ZA201203316B (en) 2013-11-27
KR20160140992A (ko) 2016-12-07
AU2009356132B2 (en) 2015-01-22
BR112012012151B1 (pt) 2021-01-19
KR20120089754A (ko) 2012-08-13
RU2526114C2 (ru) 2014-08-20
JP2013512262A (ja) 2013-04-11
CN102271659A (zh) 2011-12-07
WO2011066684A1 (zh) 2011-06-09
PL2508170T3 (pl) 2015-12-31

Similar Documents

Publication Publication Date Title
CY1116811T1 (el) Λιποσωμα ιρινοτεκανης ή του υδροχλωριδιου αυτης και μεθοδος παρασκευης αυτου
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
EA201190242A1 (ru) Липидные композиции
CY1122964T1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
CY1123774T1 (el) Στελεχη shigella me υπερφυσαλιδωση
CY1125061T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει δροσπιρενονη για χρηση ως ενα αντισυλληπτικο
CY1119843T1 (el) Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης
CY1121744T1 (el) Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων
EA201200537A1 (ru) Способ получения глюкопиранозил-замещенных производных бензилбензола
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CY1116940T1 (el) Φλυκταινες εμπλουτισμενες σε φωσφολιπιδιο που φερουν παραγοντα ιστου εχουσες αιμοστατικες δραστικοτητες και χρησεις αυτων
CY1119657T1 (el) Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
CR11659A (es) Inhibidores de hsp90
CY1119762T1 (el) C-17-ετεροαρυλικα παραγωγα ελαιολικου οξεος και μεθοδοι χρησης αυτων
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
CY1118004T1 (el) Αναστολεις cdk
CY1111830T1 (el) Παραγωγα πυριδινης ως ρυθμιστες υποδοχεων s1p1/edg1
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
EP2647644A4 (en) 2'-O-MODIFIED RNA
BR112013023456A2 (pt) "composições imunoterapêuticas de levedura brachyury, seus usos e método de produção das mesmas"
EA201100517A1 (ru) Способ получения дабигатрана и его промежуточные соединения
BR112013014598A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênica estável, e, kit